A Stock Investor’s Guide to Navigating Weight Loss Opportunities
Syringe makers, drug distributors seen among the winners from boom in obesity medicines
Photographer: Peter Dazeley/The Image Bank/Getty Images
This article is for subscribers only.
For investors, there's a whole lot more to the boom in demand for weight-loss drugs than the rising stock prices of Novo Nordisk A/S and Eli Lilly & Co.
While Ozempic maker Novo has surged into pole position as Europe's biggest company by market value, the question on the minds of many fund managers is what other stocks and sectors stand to benefit. And just as importantly, who is likely to lose.